Form 8-K
8-K — IMMUNIC, INC.
Accession: 0001193805-26-001432
Filed: 2026-11-05
Period: 2026-11-05
CIK: 0001280776
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — e665870_8k-immunic.htm (Primary)
EX-99.1 (e665870_ex99-1.htm)
GRAPHIC (slide1.jpg)
GRAPHIC (slide2.jpg)
GRAPHIC (slide3.jpg)
GRAPHIC (slide4.jpg)
GRAPHIC (slide5.jpg)
GRAPHIC (slide6.jpg)
GRAPHIC (slide7.jpg)
GRAPHIC (slide8.jpg)
GRAPHIC (slide9.jpg)
GRAPHIC (slide10.jpg)
GRAPHIC (slide11.jpg)
GRAPHIC (slide12.jpg)
GRAPHIC (slide13.jpg)
GRAPHIC (slide14.jpg)
GRAPHIC (slide15.jpg)
GRAPHIC (slide16.jpg)
GRAPHIC (slide17.jpg)
GRAPHIC (slide18.jpg)
GRAPHIC (slide19.jpg)
GRAPHIC (slide20.jpg)
GRAPHIC (slide21.jpg)
GRAPHIC (slide22.jpg)
GRAPHIC (slide23.jpg)
GRAPHIC (slide24.jpg)
GRAPHIC (slide25.jpg)
GRAPHIC (slide26.jpg)
GRAPHIC (slide27.jpg)
GRAPHIC (slide28.jpg)
GRAPHIC (slide29.jpg)
GRAPHIC (slide30.jpg)
GRAPHIC (slide31.jpg)
GRAPHIC (slide32.jpg)
GRAPHIC (slide33.jpg)
GRAPHIC (slide34.jpg)
GRAPHIC (slide35.jpg)
GRAPHIC (slide36.jpg)
GRAPHIC (slide37.jpg)
GRAPHIC (slide38.jpg)
GRAPHIC (slide39.jpg)
GRAPHIC (slide40.jpg)
GRAPHIC (slide41.jpg)
GRAPHIC (slide42.jpg)
GRAPHIC (slide43.jpg)
GRAPHIC (slide44.jpg)
GRAPHIC (slide45.jpg)
GRAPHIC (slide46.jpg)
GRAPHIC (slide47.jpg)
GRAPHIC (slide48.jpg)
GRAPHIC (slide49.jpg)
GRAPHIC (slide50.jpg)
GRAPHIC (slide51.jpg)
GRAPHIC (slide52.jpg)
GRAPHIC (slide53.jpg)
GRAPHIC (slide54.jpg)
GRAPHIC (slide55.jpg)
GRAPHIC (slide56.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: e665870_8k-immunic.htm · Sequence: 1
false
0001280776
0001280776
2026-11-05
2026-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 5, 2026
IMMUNIC, INC.
(Exact name of registrant as specified in its
charter)
Delaware
001-36201
56-2358443
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1200 Avenue of the Americas, Suite 200
New York, NY 10036
USA
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (332) 255-9818
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of exchange on which registered
Common Stock, par value $0.0001
IMUX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Item 7.01. Regulation FD Disclosure
On November 5, 2026, Immunic, Inc. (the “Company”
or “Immunic”) is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar (the “PMS
R&D Day”). The PMS R&D Day will take place on Thursday, November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video
conference. The Company intends to use a presentation during the PMS R&D Day (the “Presentation”) which is attached
as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this Current Report on Form 8-K and the Presentation
are “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current
Report on Form 8-K, and the Presentation, regarding strategy, future operations, future financial position, future revenue, projected
expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives
of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's
development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical
and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial
in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals;
the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any
product candidates of the company; Immunic’s continued listing on The Nasdaq Capital Market; and expectations regarding the capitalization,
resources and ownership structure of the company and its executive and board structure. Immunic may not actually achieve the plans, carry
out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial
risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomic trends, impacts of the Ukraine
- Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with
the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability
of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier
preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target
markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual
property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological
changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk
Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February
26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings.
Any forward-looking statement made in this Current Report on Form 8-K and the Presentation, speaks only as of the date of this Current
Report on Form 8-K, and the Presentation. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect
events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions
taken or not taken based on any or all of the contents of this Current Report on Form 8-K and the Presentation.
Item 9.01. Financial Statements and Exhibits.
Exhibit
Description
99.1
Presentation, dated November 5, 2026
104
Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: November 5, 2026
Immunic, Inc.
By:
/s/ Erik
Lundgren
Erik Lundgren
Chief Executive Officer
EX-99.1
EX-99.1
Filename: e665870_ex99-1.htm · Sequence: 2
GRAPHIC
GRAPHIC
Filename: slide1.jpg · Sequence: 6
Binary file (78969 bytes)
Download slide1.jpg
GRAPHIC
GRAPHIC
Filename: slide2.jpg · Sequence: 7
Binary file (349652 bytes)
Download slide2.jpg
GRAPHIC
GRAPHIC
Filename: slide3.jpg · Sequence: 8
Binary file (126875 bytes)
Download slide3.jpg
GRAPHIC
GRAPHIC
Filename: slide4.jpg · Sequence: 9
Binary file (163284 bytes)
Download slide4.jpg
GRAPHIC
GRAPHIC
Filename: slide5.jpg · Sequence: 10
Binary file (41629 bytes)
Download slide5.jpg
GRAPHIC
GRAPHIC
Filename: slide6.jpg · Sequence: 11
Binary file (102927 bytes)
Download slide6.jpg
GRAPHIC
GRAPHIC
Filename: slide7.jpg · Sequence: 12
Binary file (165592 bytes)
Download slide7.jpg
GRAPHIC
GRAPHIC
Filename: slide8.jpg · Sequence: 13
Binary file (175767 bytes)
Download slide8.jpg
GRAPHIC
GRAPHIC
Filename: slide9.jpg · Sequence: 14
Binary file (93319 bytes)
Download slide9.jpg
GRAPHIC
GRAPHIC
Filename: slide10.jpg · Sequence: 15
Binary file (66210 bytes)
Download slide10.jpg
GRAPHIC
GRAPHIC
Filename: slide11.jpg · Sequence: 16
Binary file (232439 bytes)
Download slide11.jpg
GRAPHIC
GRAPHIC
Filename: slide12.jpg · Sequence: 17
Binary file (194133 bytes)
Download slide12.jpg
GRAPHIC
GRAPHIC
Filename: slide13.jpg · Sequence: 18
Binary file (140786 bytes)
Download slide13.jpg
GRAPHIC
GRAPHIC
Filename: slide14.jpg · Sequence: 19
Binary file (122892 bytes)
Download slide14.jpg
GRAPHIC
GRAPHIC
Filename: slide15.jpg · Sequence: 20
Binary file (126291 bytes)
Download slide15.jpg
GRAPHIC
GRAPHIC
Filename: slide16.jpg · Sequence: 21
Binary file (140096 bytes)
Download slide16.jpg
GRAPHIC
GRAPHIC
Filename: slide17.jpg · Sequence: 22
Binary file (116146 bytes)
Download slide17.jpg
GRAPHIC
GRAPHIC
Filename: slide18.jpg · Sequence: 23
Binary file (131834 bytes)
Download slide18.jpg
GRAPHIC
GRAPHIC
Filename: slide19.jpg · Sequence: 24
Binary file (107937 bytes)
Download slide19.jpg
GRAPHIC
GRAPHIC
Filename: slide20.jpg · Sequence: 25
Binary file (93319 bytes)
Download slide20.jpg
GRAPHIC
GRAPHIC
Filename: slide21.jpg · Sequence: 26
Binary file (48009 bytes)
Download slide21.jpg
GRAPHIC
GRAPHIC
Filename: slide22.jpg · Sequence: 27
Binary file (60011 bytes)
Download slide22.jpg
GRAPHIC
GRAPHIC
Filename: slide23.jpg · Sequence: 28
Binary file (195753 bytes)
Download slide23.jpg
GRAPHIC
GRAPHIC
Filename: slide24.jpg · Sequence: 29
Binary file (175829 bytes)
Download slide24.jpg
GRAPHIC
GRAPHIC
Filename: slide25.jpg · Sequence: 30
Binary file (158850 bytes)
Download slide25.jpg
GRAPHIC
GRAPHIC
Filename: slide26.jpg · Sequence: 31
Binary file (142559 bytes)
Download slide26.jpg
GRAPHIC
GRAPHIC
Filename: slide27.jpg · Sequence: 32
Binary file (153748 bytes)
Download slide27.jpg
GRAPHIC
GRAPHIC
Filename: slide28.jpg · Sequence: 33
Binary file (193483 bytes)
Download slide28.jpg
GRAPHIC
GRAPHIC
Filename: slide29.jpg · Sequence: 34
Binary file (130074 bytes)
Download slide29.jpg
GRAPHIC
GRAPHIC
Filename: slide30.jpg · Sequence: 35
Binary file (137520 bytes)
Download slide30.jpg
GRAPHIC
GRAPHIC
Filename: slide31.jpg · Sequence: 36
Binary file (173996 bytes)
Download slide31.jpg
GRAPHIC
GRAPHIC
Filename: slide32.jpg · Sequence: 37
Binary file (136535 bytes)
Download slide32.jpg
GRAPHIC
GRAPHIC
Filename: slide33.jpg · Sequence: 38
Binary file (166415 bytes)
Download slide33.jpg
GRAPHIC
GRAPHIC
Filename: slide34.jpg · Sequence: 39
Binary file (102835 bytes)
Download slide34.jpg
GRAPHIC
GRAPHIC
Filename: slide35.jpg · Sequence: 40
Binary file (69015 bytes)
Download slide35.jpg
GRAPHIC
GRAPHIC
Filename: slide36.jpg · Sequence: 41
Binary file (110438 bytes)
Download slide36.jpg
GRAPHIC
GRAPHIC
Filename: slide37.jpg · Sequence: 42
Binary file (140047 bytes)
Download slide37.jpg
GRAPHIC
GRAPHIC
Filename: slide38.jpg · Sequence: 43
Binary file (129381 bytes)
Download slide38.jpg
GRAPHIC
GRAPHIC
Filename: slide39.jpg · Sequence: 44
Binary file (100941 bytes)
Download slide39.jpg
GRAPHIC
GRAPHIC
Filename: slide40.jpg · Sequence: 45
Binary file (61690 bytes)
Download slide40.jpg
GRAPHIC
GRAPHIC
Filename: slide41.jpg · Sequence: 46
Binary file (184788 bytes)
Download slide41.jpg
GRAPHIC
GRAPHIC
Filename: slide42.jpg · Sequence: 47
Binary file (160818 bytes)
Download slide42.jpg
GRAPHIC
GRAPHIC
Filename: slide43.jpg · Sequence: 48
Binary file (127489 bytes)
Download slide43.jpg
GRAPHIC
GRAPHIC
Filename: slide44.jpg · Sequence: 49
Binary file (126244 bytes)
Download slide44.jpg
GRAPHIC
GRAPHIC
Filename: slide45.jpg · Sequence: 50
Binary file (122670 bytes)
Download slide45.jpg
GRAPHIC
GRAPHIC
Filename: slide46.jpg · Sequence: 51
Binary file (124606 bytes)
Download slide46.jpg
GRAPHIC
GRAPHIC
Filename: slide47.jpg · Sequence: 52
Binary file (193811 bytes)
Download slide47.jpg
GRAPHIC
GRAPHIC
Filename: slide48.jpg · Sequence: 53
Binary file (112958 bytes)
Download slide48.jpg
GRAPHIC
GRAPHIC
Filename: slide49.jpg · Sequence: 54
Binary file (215454 bytes)
Download slide49.jpg
GRAPHIC
GRAPHIC
Filename: slide50.jpg · Sequence: 55
Binary file (166004 bytes)
Download slide50.jpg
GRAPHIC
GRAPHIC
Filename: slide51.jpg · Sequence: 56
Binary file (187352 bytes)
Download slide51.jpg
GRAPHIC
GRAPHIC
Filename: slide52.jpg · Sequence: 57
Binary file (121886 bytes)
Download slide52.jpg
GRAPHIC
GRAPHIC
Filename: slide53.jpg · Sequence: 58
Binary file (56249 bytes)
Download slide53.jpg
GRAPHIC
GRAPHIC
Filename: slide54.jpg · Sequence: 59
Binary file (90318 bytes)
Download slide54.jpg
GRAPHIC
GRAPHIC
Filename: slide55.jpg · Sequence: 60
Binary file (33396 bytes)
Download slide55.jpg
GRAPHIC
GRAPHIC
Filename: slide56.jpg · Sequence: 61
Binary file (159658 bytes)
Download slide56.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 63
v3.26.3
Cover
Nov. 05, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Nov. 05, 2026
Entity File Number
001-36201
Entity Registrant Name
IMMUNIC, INC.
Entity Central Index Key
0001280776
Entity Tax Identification Number
56-2358443
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
1200 Avenue of the Americas
Entity Address, Address Line Two
Suite 200
Entity Address, City or Town
New York
Entity Address, State or Province
NY
Entity Address, Country
US
Entity Address, Postal Zip Code
10036
City Area Code
(332)
Local Phone Number
255-9818
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.0001
Trading Symbol
IMUX
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration